Urovant Sciences Ltd.
UROV
UROV was delisted on the 26th of March, 2021.
27 hedge funds and large institutions have $64.3M invested in Urovant Sciences Ltd. in 2019 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
42% more funds holding
Funds holding: 19 → 27 (+8)
16% more capital invested
Capital invested by funds: $55.3M → $64.3M (+$9M)
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$3.22M |
| 2 |
WCM
Wildcat Capital Management
New York
|
+$1.91M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$434K |
| 4 |
LA
LVW Advisors
Pittsford,
New York
|
+$341K |
| 5 |
Goldman Sachs
New York
|
+$157K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.47M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.18M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$347K |
| 4 |
SCM
Sio Capital Management
New York
|
-$271K |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$217K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
26
Prelude Capital Management
New York
| $2K | -$1.16K | -134 | -45% |
|
27
Barclays
London,
United Kingdom
| $1K | +$1.29K | +149 | New |
|
|
EAM
28
Eventide Asset Management
Boston,
Massachusetts
| – | -$3.18M | -401,558 | Closed |
|
|
AAMU
29
Amundi Asset Management US
Boston,
Massachusetts
| – | -$128K | -16,186 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$7K | -914 | Closed |
|
UROV Hedge Fund Activity: Q3 2019 in Review
27 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Urovant Sciences Ltd. (UROV) for Q3 2019, worth a combined $64.3M — up 16% from $55.3M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new UROV positions and 3 closed out — a net gain of 8 holders — while 2 added to existing stakes and 8 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $3.22M. The largest seller was Millennium Management, cutting an estimated $3.47M.
- 27 institutional investors held Urovant Sciences Ltd. (UROV) as of Q3 2019, up from 19 in Q2 2019.
- Funds reported $64.3M of Urovant Sciences Ltd. stock for Q3 2019, up 16% quarter-over-quarter.
- 11 funds opened new Urovant Sciences Ltd. positions in Q3 2019 and 3 closed out, a net change of +8 holders.
- The largest Urovant Sciences Ltd. buyer in Q3 2019 was Perceptive Advisors, an estimated $3.22M added.
- The largest Urovant Sciences Ltd. seller in Q3 2019 was Millennium Management, an estimated $3.47M sold.
Based on aggregated 13F filings for Q3 2019.